Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and should not be administered with other antiretroviral products. Furthermore, Biktarvy contains tenofovir alafenamide and emtricitabine and should not be administered with tenofovir-DF or additional emtricitabine (both components of Truvada).
Biktarvy should not be co-administered with other antiretroviral medicinal products.
Biktarvy Summary of Product Characteristics, Gilead Sciences Ltd, June 2019.
As Biktarvy is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.
Biktarvy Prescribing Information, Gilead Sciences Inc, August 2019.
Emtricitabine/tenofovir-DF should not be administered concomitantly with other medicinal products containing emtricitabine or tenofovir alafenamide.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking